Scientific Program
STATE OF ART LECTURES |
|
VASCULAR BIOLOGY |
|
| Inflammation and Atherosclerosis: Novel Targets for Plaque Progression and Regression | |
| Stanley Hazen (Cleveland, OH) | Dysfunctional HDL – Lipoprotein at the crossroads of inflammation, oxidant stress and reverse cholesterol transport |
| Gwendalyn Randolph (New York, NY) | Dendritic cell and macrophage emigration from atheromatous plaque |
| Christian Weber (Aachen, DE) | Progenitor cell trafficking to the vessel wall |
| Endothelial and Vascular Cell Signaling | |
| William Sessa (New Haven, CT) | Molecular control of angiogenesis and remodeling |
| Susan Smyth (Lexington, KY) | Regulation of vascular cell function by bioactive lysolipids |
| Charles Serhan (Boston, MA) | Systems approach to inflammation-resolution: Identification of novel anti-inflammatory and pro-resolving lipid mediators |
| Endothelial Progenitor Cell Biology | |
| Mervin Yoder (Indianapolis, IN) | Defining and characterizing human endothelial progenitor cells |
| Shahin Rafii (New York, NY) | Regulation of stem cell niche by endothelium |
| Lena Claesson-Welsh (Uppsala, SE) | Embryonic stem cell- derived endothelial cells, properties and potential |
| Cues to Create a Mature Vasculature | |
| Dean Li (Salt Lake City, UT) | Guidance signals that promote vascular stability |
| Anne Eichman (Paris, FR) | Receptors involved in guiding vascular cells |
| Brant Weinstein (Bethesda, MD) | Signaling pathways regulating angiogenesis |
HEMORRHAGIC DISORDERS |
|
| Von Willebrand Disease - New Developments | |
| Cecile Denis (Paris, FR) | Mouse models of von Willebrand disease |
| David Lillicrap (Kingston, CA) | Genotype/phenotype association in von Willebrand disease: Is the glass half full or empty? |
| Giancarlo Castaman (Vicenza, IT) | Reduced VWF survival in VWD: pathophysiological and clinical relevance |
| Factor XI Revisited | |
| David Gailani (Nashville, TN) | Structural and functional features of factor XI |
| Thomas Renné (Wurzburg, DE) | Factor XI deficiency in animal models |
| Uri Seligsohn (Tel-Hashomer, IL) | Factor XI deficiency in humans |
| Burning Questions in Hemophilia Inhibitors | |
| Ronald Herzog (Gainesville, FL) | The role of regulatory T cells in tolerance to coagulation factors |
| Birgit Reipert (Vienna, AT) | Opportunities and limitations of mouse models humanized for HLA class II antigens |
| Marijke van den Berg (Utrecht, NL) | Clinical prediction models for inhibitor development |
| Acquired Bleeding Disorders | |
| Marcel Levi (Amsterdam, NL) | Epidemiology and management of bleeding in patients using vitamin K antagonists |
| Mark Crowther (Hamilton, CA) | Bleeding with the new anticoagulants: Management options |
| George Despotis (St. Louis, MO) | Prediction and management of bleeding after cardiac surgery |
COAGULATION AND FIBRINOLYSIS |
|
| Inflammation and Coagulation | |
| Wolfram Ruf (San Diego, CA) | Dendritic cells and PAR signaling in inflammation |
| Anthony Dorling (London, UK) | Critical roles for thrombin in acute and chronic inflammation |
| Hartmut Weiler (Milwaukee, WI) | Modulation of sepsis with activated protein C variants |
| Blood Coagulation-Systemic Effects in vivo | |
| David Ginsburg (Ann Arbor, MI) | Modifier genes for disorders of thrombosis and hemostasis |
| Nigel Mackman (Chapel Hill, NC) | The many faces of tissue factor |
| Francis Castellino (Notre Dame, IN) | The role of the protein C system in pathologic processes |
| Fibrinogen/Fibrinolysis in the Brain | |
| Sidney Strickland (New York, NY) | The role of fibrin in Alzheimer's Disease |
| Katerina Akassoglou (San Francisco, CA) | Fibrinogen signal transduction in the nervous system |
| Daniel Lawrence (Ann Arbor, MI) | tPA and neurovascular coupling in stroke |
| Novel Regulatory Reactions in Coagulation | |
| James Huntington (Cambridge, UK) | Protease allostery in hemostasis |
| Tilman Hackeng (Maastricht, NL) | Regulation of TFPI function by protein S |
| James Morrissey (Urbana, IL) | Blood clotting reactions on nanoscale bilayers |
PLATELETS (BASIC) |
|
| Novel Approaches to Understanding Hemostasis | |
| Joseph Italiano (Boston, MA) | Selective sorting of platelet ?-granule contents |
| Scott Diamond (Philadelphia, PA) | Systems biology of platelets and coagulation |
| Kathleen Brummel-Ziedins (Colchester, VT) | Empirical and theoretical phenotypic discrimination in hemostasis |
| Platelet Activation | |
| Wolfgang Bergmeier (Philadelphia, PA) | Novel molecules in calcium signaling in platelets |
| Yukio Ozaki (Yamanashi, JP) | Novel interactions in platelet biology |
| Debra Newman (Milwaukee, WI) | The Y's that bind: negative regulators of platelet activation |
| Integrin Biology | |
| Joel Bennett (Philadelphia, PA) | Integrin structure |
| Bernhardt Nieswandt (Wurzburg, DE) | Integrins in platelet activation |
| Sanford Shattil (La Jolla, CA) | Platelets and integrin signaling |
| Platelet Physiology/Pathophysiology | |
| Benjamin Kile (Parkville, AU) | The role of the intrinsic apoptosis pathway in platelet biogenesis, life and death |
| Eugene Podrez (Cleveland, OH) | Platelet hyperreactivity, scavenger receptors and atherothrombosis |
| Garrett FitzGerald (Philadelphia, PA) | Bioactive lipids and atherothrombosis |
PLATELETS (CLINICAL) |
|
| Thrombopoietin Receptor Agonists | |
| William Vainchecker (Villejuif, FR) | Regulation of megakaryocyte maturation and platelet formation |
| Kenneth Kaushansky (San Diego, CA) | Molecular mechanisms of thrombopoietin signaling |
| Yasuo Ikeda (Tokyo, JP) | Development of thrombopoietin receptor agonists for clinical use |
| Immune Thrombocytopenia | |
| Alan Lazarus (Toronto, CA) | New insight into the mechanism of action of IV immunoglobulin |
| Mortimer Poncz (Philadelphia, PA) | Pathogenesis of heparin-induced thrombocytopenia (HIT): Clinical implications |
| James Bussel (New York, NY) | Fetal and neonatal alloimmune thrombocytopenia |
| Platelet Inhibition | |
| Carlo Patrono (Roma, IT) | Aspirin: 110 years later |
| Marco Cattaneo (Milano, IT) | New P2Y12 antagonists |
| Richard Becker (Durham, NC) | The evolution of platelet-directed pharmacotherapy |
| Inherited Platelet Disorders | |
| Ramesh Shivdasani (Boston, MA) | Regulation of platelet biogenesis |
| Alan Nurden (Pessac, FR) | Altered megakaryopoiesis in Type IIb von Willebrand disease |
| Christel Van Geet (Leuven, BE) | Lesions in platelet signaling |
THROMBOTIC DISORDERS |
|
| Anticoagulation Duration after Idiopathic Venous Thrombosis - the Swinging Pendulum | |
| Trevor Baglin (Cambridge, UK) | What happens after venous thromboembolism? |
| Sabine Eichinger (Vienna, AT) | Risk assessment to predict recurrence |
| Clive Kearon (Hamilton, CA) | Balancing risks and benefits of extended anticoagulation |
| Genomics and Vascular Disease: What Have We Learned About Thrombosis? | |
| Frits Rosendaal (Leiden, NL) | Genetics of venous thrombosis |
| Willem Ouwehand (Cambridge, UK) | The discovery of genes implicated in myocardial infarction |
| Bruce Psaty (Seattle, WA) | Genome wide association studies: Atherosclerosis & risk factors |
| Pulmonary Embolism, 2009 | |
| Menno Huisman (Leiden, NL) | Diagnostic management of pulmonary embolism |
| Drahomir Aujesky (Lausanne, CH) | Short term prognosis of pulmonary embolism |
| Samuel Goldhaber (Boston, MA) | Treatment strategies including thrombolysis and embolectomy |
| Inflammation and Atherosclerosis: A Paradigm Shift? | |
| Goran Hansson (Stockholm, SE) | Inflammation and atherosclerosis: Pathophysiology |
| John Danesh (Cambridge, UK) | Epidemiology of inflammation and atherosclerosis |
| Paul Ridker (Boston, MA) | Clinical interventions for inflammation |